Senaparib
Small moleculeexperimental
Clinical trial activity
16 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
12
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Feb 3, 2017 (NCT03507543)
Timeline
Indications
Mechanism of action
- Poly [ADP-ribose] polymerase 4INHIBITOR
PARP4 inhibitor
- Poly [ADP-ribose] polymerase 2INHIBITOR
Poly [ADP-ribose] polymerase 2 inhibitor
- Poly [ADP-ribose] polymerase-1INHIBITOR
Poly [ADP-ribose] polymerase-1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(c1cc(Cn2c(=O)[nH]c(=O)c3c(F)cccc32)ccc1F)N1CCN(c2ncccn2)CC1- Mol. weight
- 478.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4802152 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07120451 | Phase 2 | Oct 10, 2025 | Fudan University |
| NCT06617923 | Phase 2 | Dec 31, 2024 | Johns Hopkins University, National Cancer Institute (NCI) |
| NCT07019194 | Phase 1 | Jun 21, 2024 | Impact Therapeutics, Inc. |
| NCT05390944 | Phase 1 | Jun 8, 2022 | Impact Therapeutics, Inc., Shanghai Xuhui District Central Hospital |
| NCT05391048 | Phase 1 | Jun 6, 2022 | Impact Therapeutics, Inc., Shanghai Xuhui District Central Hospital |
| NCT05262842 | Phase 1 | Mar 29, 2022 | Shanghai Junshi Bioscience Co.,Ltd., Sponsor GmbH, Sun Yat-Sen University |
| NCT04822961 | Phase 2 | Oct 31, 2021 | Impact Therapeutics, Inc. |
| NCT05109832 | Phase 1 | Oct 30, 2021 | Impact Therapeutics, Inc. |
| NCT07030439 | Phase 1 | Jul 18, 2021 | Impact Therapeutics, Inc., Shanghai Xuhui District Central Hospital |
| NCT04584515 | Phase 1 | Nov 2, 2020 | Central South University, Impact Therapeutics, Inc. |
| NCT04434482 | Phase 1 | Jun 30, 2020 | Impact Therapeutics, Inc. |
| NCT04351165 | Phase 1 | Apr 30, 2020 | Impact Therapeutics, Inc. |
| NCT04089189 | Phase 2 | Sep 30, 2019 | Impact Therapeutics, Inc. |
| NCT04057729 | Phase 1 | Jul 22, 2019 | Impact Therapeutics, Inc. |
| NCT03508011 | Phase 1 | Aug 23, 2017 | Chinese Academy of Medical Sciences, Fudan University, Impact Therapeutics, Inc. |
| NCT03507543 | Phase 1 | Feb 3, 2017 | Impact Therapeutics, Inc., Monash University |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Impact Therapeutics, Inc. | For profit | 13 | 13 | 2 | 2017 |
| Shanghai Xuhui District Central Hospital | Academic/Hospital | 3 | 0 | 1 | 2021 |
| Fudan University | Academic/Hospital | 2 | 1 | 2 | 2017 |
| Central South University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Monash University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2024 |
| Shanghai Junshi Bioscience Co.,Ltd. | For profit | 1 | 1 | 1 | 2022 |
| Sponsor GmbH | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2022 |
11 organizations
Page 1 / 1